In a previous study, we found that a majority of patients maintain their weight loss a year after stopping GLP-1 use.1 To further understand what factors might influence whether patients were likely to maintain, regain, or lose more weight, we studied 25,552 patients prescribed semaglutide and 33,456 patients prescribed liraglutide for at least 90 days continuously between January 1, 2017, and February 1, 2023.
In the year following discontinuation of semaglutide or liraglutide, patients with class 3 obesity–a BMI of 40 or greater–when starting a GLP-1 medication were much more likely to maintain or lose additional weight compared to those who started treatment with a healthy weight–a BMI between 18.5 and 25. Among patients prescribed semaglutide, 62% of patients with class 3 obesity maintained or continued to lose weight after one year, compared to 37% of patients with a healthy BMI. Patients prescribed liraglutide saw similar rates with 62% of patients with class 3 obesity and 45% of patients with a healthy BMI maintaining or losing additional weight after one year.
We also found that patients who lost at least 40 pounds while on semaglutide or liraglutide were more likely to maintain or continue their weight loss one year after the end of their treatment compared to those who lost less weight during treatment. Of patients who lost at least 40 pounds, 67% prescribed semaglutide and 68% prescribed liraglutide either maintained their weight or continued to lose additional weight one year after ending treatment.
Patients who were prescribed semaglutide or liraglutide for at least one year were slightly more likely to maintain or continue to lose weight in the year following treatment. More than half of patients prescribed semaglutide or liraglutide for all treatment durations studied were able to maintain or continue their weight loss one year after treatment.